Skip to content
value.today

Revance Therapeutics, Inc.

Total raised
$78 M
3 rounds on record
Latest round
$10 M
Oct 2013
First round on record
Jan 2011
Today
Private
No later event on record

Funding rounds

3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Revance Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2013$10 MNo. 3$10 to $50 million

Revance Therapeutics, Inc.: Raise no. 3, Oct 2013

Investors in this round

4 investors had bought by the notice of Oct 23, 2013: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Revance Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $30 M offered; $20 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel L. Browne · Executive Officer, Director
  • Frank L. Kung · Director
  • Jim L. Glasheen · Director
  • Jonathan L. Tunnicliffe · Director
  • Phyllis L. Gardner · Director
  • Robert L. Byrnes · Director
  • Ronald L. Eastman · Director
  • Vicente L. Trelles · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Lauren Silvernail, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 23, 2013. Read the notice at the SEC.

equity, debtSEC
Feb 2013$5 MNo. 2$2 to $10 million

Revance Therapeutics, Inc.: Raise no. 2, Feb 2013

Investors in this round

4 investors had bought by the notice of Feb 22, 2013: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Revance Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $60 M offered; $55 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • L. Daniel Browne · Executive Officer, Director
  • Frank Daniel Kung · Director
  • Jim Daniel Glasheen · Director
  • Jonathan Daniel Tunnicliffe · Director
  • Phyllis Daniel Gardner · Director
  • Robert Daniel Byrnes · Director
  • Ronald Daniel Eastman · Director
  • Vicente Daniel Trelles · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Series E Preferred Stock and the underlying Common Stock issuable upon conversion thereof”

Signed by David Styka, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 22, 2013. Read the notice at the SEC.

equitySEC
Jan 2011$63 MNo. 1$50 to $250 million

Revance Therapeutics, Inc.: Raise no. 1, Jan 2011

Investors in this round

33 investors had bought by the notice of Jan 9, 2013: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Revance Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$63 M of $63 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • L. Daniel Browne · Executive Officer, Director
  • Frank Daniel Kung · Director
  • Jim Daniel Glasheen · Director
  • Jonathan Daniel Tunnicliffe · Director
  • Phyllis Daniel Gardner · Director
  • Robert Daniel Byrnes · Director
  • Ron Daniel Eastman · Director
  • Vicente Daniel Trelles · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “Issuance of Secured Subordinated Convertible Promissory Notes and Warrants to purchase Common Stock and the underlying Preferred and Common Stock issuable upon exercise and conversion thereof”

Signed by Craig Dauchy, Secretary. Source: SEC Form D and 3 amendments, newest notice filed Jan 9, 2013. Read the notice at the SEC.

equity, debt, optionsSEC
Dec 2009$36 MIssued in a merger or acquisition$10 to $50 million

Revance Therapeutics, Inc.: Private sale, Dec 2009

Investors in this round

27 investors had bought by the notice of Nov 18, 2010: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Revance Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$36 M of $36 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: "Offering of Series D Preferred Stock (""Series D""), and the underlying shares of Common Stock issuable upon conversion of the Series D."
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • L. Daniel Browne · Executive Officer, Director
  • Frank Daniel Kung · Director
  • Jim Daniel Glasheen · Director
  • Phyllis Daniel Gardner · Director
  • Robert Daniel Byrnes · Director
  • Vicente Daniel Trelles · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “$5,666,370.73 of the Issuer?s Series D was issued in exchange for outstanding principal and accrued interest on convertible notes issued by the Company and $30,570,562.22 of the Issuer's Series D was issued in connection with a venture capital financing”
  • On a merger: “$5,666,370.73 of the Issuer?s Series D was issued in exchange for outstanding principal and accrued interest on convertible notes issued by the Company and $30,570,562.22 of the Issuer's Series D was issued in connection with a venture capital financing.”

Signed by L. Daniel Browne, President and CEO. Source: SEC Form D and 3 amendments, newest notice filed Nov 18, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Revance Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2013).

    SEC Form D · Oct 2013

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Oct 2013

That is all the official record says: Revance Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

7 named in official filings. Open an investor to see everything it has backed.

Investors in Revance Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Essex Woodlands Health Ventures Fund VIII-A LPVenture capitalnot statednot statedHeld Series E-3, E-4 and E-5 preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Essex Woodlands Health Ventures Fund VIII-B LPVenture capitalnot statednot statedHeld Series E-3, E-4 and E-5 preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Essex Woodlands Health Ventures Fund VIII LPVenture capitalnot statednot statedHeld Series E-3, E-4 and E-5 preferred stock, 10% owner (Form 3, 2014)SEC Form 3
L. Daniel BrownePersonnot statednot statedHeld Series E-1 preferred stock, director (Form 3, 2014)SEC Form 3
NovaQuest Pharma Opportunities Fund III, L.P.Fund or asset managernot statednot statedHeld Series E-4 and E-5 preferred stock, 10% owner (Form 3, 2014)SEC Form 3
NQ HCIF General Partner, L.P.Fund or asset managernot statednot statedHeld Series E-4 and E-5 preferred stock, 10% owner (Form 3, 2014)SEC Form 3
NQ HCIF GP, Ltd.Companynot statednot statedHeld Series E-4 and E-5 preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 33 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Revance Therapeutics, Inc.
NameRoleNamed in
Daniel L. BrowneExecutive officerOct 2013
L. Daniel BrowneExecutive officerFeb 2013
Daniel L. BrowneDirectorOct 2013
Frank L. KungDirectorOct 2013
Jim L. GlasheenDirectorOct 2013
Jonathan L. TunnicliffeDirectorOct 2013
Phyllis L. GardnerDirectorOct 2013
Robert L. ByrnesDirectorOct 2013
Ronald L. EastmanDirectorOct 2013
Vicente L. TrellesDirectorOct 2013
Frank Daniel KungDirectorFeb 2013
Jim Daniel GlasheenDirectorFeb 2013
Jonathan Daniel TunnicliffeDirectorFeb 2013
L. Daniel BrowneDirectorFeb 2013
Phyllis Daniel GardnerDirectorFeb 2013
Robert Daniel ByrnesDirectorFeb 2013
Ronald Daniel EastmanDirectorFeb 2013
Vicente Daniel TrellesDirectorFeb 2013
Ron Daniel EastmanDirectorJan 2013